Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThermoDox + Hyperthermia + RT for Recurrent Breast Cancer
NCT02850419Phase 2Withdrawn
- Sponsor
- Imunon, Inc.
- Start
- Mar 2017
- Primary completion
- Dec 2019
- Modality
- Lipid-based Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of ThermoDox in breast cancer, sponsored by Imunon, Inc. Primary endpoints: Number of participants with treatment-related adverse events at 12 months and Loco-regional breast tumor control at 18 months. Planned start Mar 2017; status: withdrawn.
02
Drugs
ThermoDox
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02850419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02850419.